Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/14767058.2015.1022864 http://scihub22266oqcxt.onion/10.3109/14767058.2015.1022864 C4710361!4710361!25893545     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Matern+Fetal+Neonatal+Med 2016 ; 29 (6): 855-62 Nephropedia Template TP {{tp|p=25893545|t=2016. Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD) |pdf=|usr=}}{{25893545}} gab.com Text Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD) JO: J Matern Fetal Neonatal Med http://www.kidney.de/pget.php?&tw=1&pmid=25893545 #FOAvip Massive perivillous fibrin deposition of the placenta (MPFD) or maternal floor infarction (MFI) is a serious condition associated with recurrent complications including fetal death and severe fetal growth restriction. There is no method to evaluate the risk of adverse outcome in subsequent pregnancies, or effective prevention. Recent observations suggest that MFI is characterized by an imbalance in angiogenic/anti-angiogenic factors in early pregnancy; therefore, determination of these biomarkers may identify the patient at risk for recurrence. We report the case of a pregnant woman with a history of four consecutive pregnancy losses, the last of which was affected by MFI. Abnormalities of the anti-angiogenic factor, sVEGFR-1, and soluble endoglin (sEng) were detected early in the index pregnancy, and treatment with pravastatin corrected the abnormalities. Treatment resulted in a live birth infant at 34 weeks of gestation who had normal biometric parameters and developmental milestones at the age of 2. This is the first reported successful use of pravastatin to reverse an angiogenic/anti-angiogenic imbalance and prevent fetal death. Twit Text FOAVip Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD) ????J Matern Fetal Neonatal Med http://www.kidney.de/pget.php?&tw=1&pmid=25893545 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25893545 #FOAvip English Wikipedia <ref>{{Cite pmid|25893545}}</ref> Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD) #MMPMID25893545 Chaiworapongsa T; Romero R; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Segars JH; DeCherney AH; McCoy MC; Kim CJ; Yeo L; Hassan SS J Matern Fetal Neonatal Med 2016[Mar]; 29 (6): 855-62 PMID25893545show ga Massive perivillous fibrin deposition of the placenta (MPFD) or maternal floor infarction (MFI) is a serious condition associated with recurrent complications including fetal death and severe fetal growth restriction. There is no method to evaluate the risk of adverse outcome in subsequent pregnancies, or effective prevention. Recent observations suggest that MFI is characterized by an imbalance in angiogenic/anti-angiogenic factors in early pregnancy; therefore, determination of these biomarkers may identify the patient at risk for recurrence. We report the case of a pregnant woman with a history of four consecutive pregnancy losses, the last of which was affected by MFI. Abnormalities of the anti-angiogenic factor, sVEGFR-1, and soluble endoglin (sEng) were detected early in the index pregnancy, and treatment with pravastatin corrected the abnormalities. Treatment resulted in a live birth infant at 34 weeks of gestation who had normal biometric parameters and developmental milestones at the age of 2. This is the first reported successful use of pravastatin to reverse an angiogenic/anti-angiogenic imbalance and prevent fetal death. äPravastatin to prevent recurrent fetal death in massive perivillous fi(epmc).pdf DeepDyve Pubget Overpricing